Loading…
Details
- Instance of
- type of chemical entity
- Subclass of
- chemical compound
- chemical formula
- C₂₂₂₄H₃₄₇₅N₆₂₁O₆₉₈S₃₆
- defined daily dose
- 7
- has characteristic
- biopharmaceutical
- has use
- medication
- legal status (medicine)
- boxed warning
- LiverTox likelihood score
- LiverTox toxicity likelihood category B
- medical condition treated
- juvenile rheumatoid arthritis, psoriatic arthritis, rheumatoid arthritis, polyarthritis, autosomal dominant familial periodic fever, osteoarthritis susceptibility 1, systemic-onset juvenile idiopathic arthritis, ankylosing spondylitis, pityriasis rubra pilaris, fibromyalgia, arthropathy, reactive arthritis
- pregnancy category
- Australian pregnancy category B2, US pregnancy category B
Connected on Wikidata
Subject of
- Etanercept Treating Patient With Acute ST Segment Elevated Myocardial Infarction
- Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)
- Etanercept (Enbrel) in Undifferentiated Spondyloarthritis
- Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®
- Etanercept for the Treatment of Chronic Urticaria
- Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity
- Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis
- Spanish Registry of Systemic Treatments in Psoriasis
- Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis
- Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
Nothing in the MetaHistoryBook collection references this item yet.